Literature DB >> 2775320

Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus.

M H Liang1, S A Socher, M G Larson, P H Schur.   

Abstract

Six systems for defining and evaluating disease activity in patients with systemic lupus erythematosus (SLE) (the Ropes system, the National Institutes of Health [NIH] system, the New York Hospital for Special Surgery system, the British Isles Lupus Assessment Group [BILAG] scale, the University of Toronto SLE Disease Activity Index [SLE-DAI], and the Systemic Lupus Activity Measure [SLAM]) were tested on 25 SLE patients who were selected to represent a range of disease activity. The patients were evaluated independently by 2 physicians on 2 occasions approximately 1 month apart. Differences between patients demonstrated the largest source of variation in scores, accounting for 56-84% of the total variance, depending on the instrument. Differences between physicians (i.e., error) showed the next largest variation, 11-28% of the total variance, and differences between visits made up 5-16% of the total. The BILAG, SLE-DAI, and SLAM had the best inter-visit and inter-rater reliability. Convergent validity was shown by the strong correlations of scores among the different instruments (r = 0.81-0.97). All instruments correlated highly with the physicians' clinical impression of disease but less well with their evaluation of disease severity. The number of American Rheumatism Association criteria for SLE that were met by the patients correlated poorly with the physicians' global evaluation and with the scores of the instruments. The patients' self-reported disease activity scores correlated highly with the physicians' assessments of disease activity (r = 0.85-0.91), and the mean values from self-reports and from physicians' assessments were nearly equal. In contrast, severity scores correlated less well between self-reports and physician assessments (r = 0.49-0.69), and mean self-reported severity values were lower than the means from physicians. The BILAG, SLE-DAI, and SLAM systems appear to have better psychometric properties than the others for clinical research.

Entities:  

Mesh:

Year:  1989        PMID: 2775320     DOI: 10.1002/anr.1780320909

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  174 in total

Review 1.  Combination treatment in autoimmune diseases: systemic lupus erythematosus.

Authors:  G Moroni; O Della Casa Alberighi; C Ponticelli
Journal:  Springer Semin Immunopathol       Date:  2001

Review 2.  Recognition and management of systemic lupus erythematosus.

Authors:  J O Schroeder; H H Euler
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

3.  Increased apoptotic peripheral blood neutrophils in systemic lupus erythematosus: relations with disease activity, antibodies to double stranded DNA, and neutropenia.

Authors:  P A Courtney; A D Crockard; K Williamson; A E Irvine; R J Kennedy; A L Bell
Journal:  Ann Rheum Dis       Date:  1999-05       Impact factor: 19.103

4.  Toward the development of criteria for global flares in juvenile systemic lupus erythematosus.

Authors:  Hermine I Brunner; Marisa S Klein-Gitelman; Gloria C Higgins; Sivia K Lapidus; Deborah M Levy; Anne Eberhard; Nora Singer; Judyann C Olson; Karen Onel; Marilynn Punaro; Laura Schanberg; Emily von Scheven; Jun Ying; Edward H Giannini
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-06       Impact factor: 4.794

5.  Association between depression and vascular disease in systemic lupus erythematosus.

Authors:  Carol M Greco; Tracy Li; Abdus Sattar; Amy H Kao; Natalya Danchenko; Daniel Edmundowicz; Kim Sutton-Tyrrell; Russell P Tracy; Lewis H Kuller; Susan Manzi
Journal:  J Rheumatol       Date:  2011-12-15       Impact factor: 4.666

6.  Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.

Authors:  Gabor G Illei; Yuko Shirota; Cheryl H Yarboro; Jimmy Daruwalla; Edward Tackey; Kazuki Takada; Thomas Fleisher; James E Balow; Peter E Lipsky
Journal:  Arthritis Rheum       Date:  2010-02

7.  Relation of platelet C4d with all-cause mortality and ischemic stroke in patients with systemic lupus erythematosus.

Authors:  Amy H Kao; Christine A McBurney; Abdus Sattar; Apinya Lertratanakul; Nicole L Wilson; Sarah Rutman; Barbara Paul; Jeannine S Navratil; Andrea Scioscia; Joseph M Ahearn; Susan Manzi
Journal:  Transl Stroke Res       Date:  2013-10-27       Impact factor: 6.829

8.  Enhanced expression of interferon-inducible protein-10 correlates with disease activity and clinical manifestations in systemic lupus erythematosus.

Authors:  K O Kong; A W Tan; B Y H Thong; T Y Lian; Y K Cheng; C L Teh; E T Koh; H H Chng; W G Law; T C Lau; K P Leong; B P Leung; H S Howe
Journal:  Clin Exp Immunol       Date:  2009-01-23       Impact factor: 4.330

9.  Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort.

Authors:  Maria I Danila; Guillermo J Pons-Estel; Jie Zhang; Luis M Vilá; John D Reveille; Graciela S Alarcón
Journal:  Rheumatology (Oxford)       Date:  2009-02-20       Impact factor: 7.580

10.  Major pathogenic steps in human lupus can be effectively suppressed by nucleosomal histone peptide epitope-induced regulatory immunity.

Authors:  Li Zhang; Anne M Bertucci; Rosalind Ramsey-Goldman; Elizabeth Randall Harsha-Strong; Richard K Burt; Syamal K Datta
Journal:  Clin Immunol       Date:  2013-08-23       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.